Curanex Pharmaceuticals (NASDAQ:CURX) Announces Earnings Results

Curanex Pharmaceuticals (NASDAQ:CURX) posted its quarterly earnings results on Friday. The company reported ($1.86) EPS for the quarter, FiscalAI reports.

Curanex Pharmaceuticals Stock Performance

NASDAQ CURX traded down $0.84 during trading on Friday, hitting $4.83. 6,252 shares of the company’s stock traded hands, compared to its average volume of 9,553. The stock has a market capitalization of $7.59 million, a price-to-earnings ratio of -0.62 and a beta of -2.99. Curanex Pharmaceuticals has a 12-month low of $3.58 and a 12-month high of $13.33. The business has a 50 day moving average of $4.94 and a 200-day moving average of $6.09.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a research report on Tuesday, October 27th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Curanex Pharmaceuticals presently has a consensus rating of “Sell”.

Curanex Pharmaceuticals Company Profile

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.